Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

Histone deacetylase inhibitors in the treatment for multiple myeloma

(2013) Teru Hideshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Panobinostat for the treatment of multiple myeloma

(2012) Paola Neri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response

(2012) Soumen Kahali et al.   FASEB JOURNAL

Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

(2012) A Rio-Machin et al.   LEUKEMIA

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

(2012) Massimo Offidani et al.   LEUKEMIA & LYMPHOMA

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

(2012) J. Moreaux et al.   MOLECULAR CANCER THERAPEUTICS

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

(2012) Alboukadel Kassambara et al.   PLoS One

The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

(2012) Philippe Moreau   SEMINARS IN HEMATOLOGY

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

(2011) S. J. Harrison et al.   BLOOD

E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation

(2011) Guodong Yang et al.   CELL CYCLE

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

(2011) A. Kassambara et al.   HAEMATOLOGICA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells

(2010) Rekha Rao et al.   MOLECULAR CANCER THERAPEUTICS

Epigenetic modifications as therapeutic targets

(2010) Theresa K Kelly et al.   NATURE BIOTECHNOLOGY

Nuclear protein IκB-ζ inhibits the activity of STAT3

(2009) Zhihao Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor

(2009) Melissa Ihla Niesen et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

RNA-Binding Protein Quaking, a Critical Regulator of Colon Epithelial Differentiation and a Suppressor of Colon Cancer

(2009) Guodong Yang et al.   GASTROENTEROLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1)

(2009) M. Hartl et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers

(2009) Yutaka Kondo   YONSEI MEDICAL JOURNAL

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

(2008) W. Xiong et al.   BLOOD

A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

(2008) Thierry Rème et al.   BMC BIOINFORMATICS

Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells

(2008) G. Heller et al.   CANCER RESEARCH

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

(2008) Rentian Feng et al.   MOLECULAR CANCER THERAPEUTICS

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE